Xbrane Biopharma (XBRANE.ST) Stock Analysis & AI Equity Report
Xbrane Biopharma (XBRANE.ST) overview
Xbrane Biopharma (XBRANE.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Xbrane Biopharma reported revenue of SEK 152m and operating profit of SEK -72.1m; the year-end share price was 10.20 SEK and market capitalisation was SEK 15,522m. Xbrane Biopharma is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Xbrane Biopharma's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Xbrane Biopharma
Xbrane Biopharma AB develops biosimilars and related biological drugs using a patented production platform designed to lower manufacturing costs. Its portfolio includes candidates for ophthalmology and oncology, including Ximluci and Xdivane, and the company also generates revenue from product sales and licensing agreements. The company is headquartered in Solna and listed on Nasdaq Stockholm.
Generate the Xbrane Biopharma report
Xbrane Biopharma is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Xbrane Biopharma and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.